Advances in Chronic Kidney Disease
Volume 17, Issue 1 , Pages 26-35, January 2010

Screening for Chronic Kidney Disease in HIV-Infected Patients

Division of Nephrology, Johns Hopkins School of Medicine, Baltimore, MD

With improved survival afforded by highly active antiretroviral therapy (HAART), CKD has emerged as one of the primary comorbid conditions affecting HIV-infected individuals. Although CKD in HIV-infected individuals is classically thought of as a consequence of advanced HIV infection such as in the case of HIV-associated nephropathy, several factors likely contribute to the development CKD in HIV infection. These factors include genetic predisposition, age-related decline in kidney function, HAART-related metabolic changes, exposure to multiple nephrotoxic medications, and concurrent conditions such as hepatitis C or illicit drug use. Similar to the general population, proteinuria and impaired kidney function are associated with faster progression to acquired immune deficiency syndrome and death. Given the prevalence and impact of kidney disease on the course of HIV infection and its management, current guidelines recommend screening all HIV-infected individuals for kidney disease. This review focuses on the current guidelines for kidney disease screening and discusses traditional as well as promising strategies for detecting CKD in this vulnerable population.

Key Words: HIV infection, Proteinuria, Estimated glomerular filtration rate, Modification of Diet in Renal Disease equation, Cystatin C

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Dr. Estrella is supported by the NIH/NIDDK grant 1K23DK081317-01A1. Dr. Fine has received consulting fees and speaker honoraria from GlaxoSmithKline

PII: S1548-5595(09)00150-5

doi:10.1053/j.ackd.2009.07.014

Advances in Chronic Kidney Disease
Volume 17, Issue 1 , Pages 26-35, January 2010